DT-diaphorase expression and tumor cell sensitivity to 17-allylamino,17- demethoxygeldanamycin, an inhibitor of heat shock protein 90

Journal of the National Cancer Institute

Volumn 91, Issue 22, 1999, Pages 1940-1949

  Kelland, Lloyd R ^a   Sharp, Swee Y ^a   Rogers, Paul M ^a   Myers, Timothy G ^b   Workman, Paul ^a,c  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (United States)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

17 AMINO,17 DEMETHOXYGELDANAMYCIN; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; RADICICOL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL GROWTH; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME ACTIVITY; ENZYME ANALYSIS; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN EXPRESSION; XENOGRAFT;

EID: 0033579175     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.22.1940     Document Type: Article

References (41)

1. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 1994;91: 8324-8.
2. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 1997;89:239-50.
3. Prodromou C, Roe SM, O'Brien RO, Ladbury JE, Piper PW, Pearl LH. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 1997;90:65-75.
4. erbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity. Cancer Chemother Pharmacol 1997;40:60-4.
5. Dasgupta G, Momand J. Geldanamycin prevents nuclear translocation of mutant p53. Exp Cell Res 1997;237:29-37.
6. Whitesell L, Sutphin PD, Pulcini EJ, Martinez JD, Cook PH. The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent. Mol Cell Biol 1998;18: 1517-24.
7. Supko JG, Hickman RL, Grever MR, Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 1995;36:305-15.
8. Schnur RC, Corman ML, Gallaschun RJ, Cooper BA, Dee MF. Doty JL, et al. erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships. J Med Chem 1995;38:3813-20.
9. Schulte TW, Neckers LM. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 1998;42: 273-9.
10. Page J, Heath J, Fulton R, Yalkowsky E, Tabibi E, Tomaszewski J, et al. Comparison of geldanamycin (NSC-122750) and 17-allylamino-geldanamycin (NSC-330507D) toxicity in rats [abstract]. Proc Am Assoc Cancer Res 1997;38:A2067.
11. Burger AM, Fiebig HH, Newman DJ, Camalier RF, Sausville EA, Antitumor activity of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in melanoma xenografts is associated with decline in Hsp90 protein expression [abstract]. Annals Oncol 1998;9(Suppl 2):abstract 504.
12. 1 mice and Fisher 344 rats [abstract]. Proc Am Assoc Cancer Res 1997;38:A2063.
13. Egorin MJ, Rosen DM, Wolff JH, Gallery PS, Musser SM, Eiseman JL. Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res 1998;58:2385-96.
14. Sharma SV, Agatsuma T, Nakano H. Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol. Oncogene 1998;16:2639-45.
15. Soga S, Kozawa T, Narumi H, Akinaga S, Irie K, Matsumoto K, et al. Radicicol leads to selective depletion of Raf kinase and disrupts K-Ras-activated aberrant signaling pathway. J Biol Chem 1998;273:822-8.
16. Schulte TW, Akinaga S, Soga S, Sullivan W, Stensgard B, Toft D, et al. Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin. Cell Stress Chaperones 1998;3:100-8.
17. Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PW, Pearl LH. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 1999;42: 260-6.
18. Ernster L. DT-diaphorase: a historical review. Chemica Scripta 1987;27A: 1-13.
19. Workman P. Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolising enzymes, particularly DT-diaphorase. Oncol Res 1994;6:461-75.
20. Riley RJ, Workman P. DT-diaphorase and cancer chemotherapy. Biochem Pharmacol 1992;43:1657-69.
21. Stratford IJ, Workman P. Bioreductive drugs into the next millennium. Anticancer Drug Des 1998;13:519-28.
22. Robertson N, Stratford IJ, Houlbrook S, Carmichael J, Adams GE. The sensitivity of human tumor cells to quinone bioreductive drugs: what role for DT-diaphorase? Biochem Pharmacol 1992;44:409-12.
23. Fitzsimmons SA, Workman P, Grever M, Paull K, Camalier R, Lewis AD. Reductase enzyme expression across the National Cancer Institute Tumor Cell Line Panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst 1996;88:259-69.
24. Ross D, Beall HD, Siegel D, Traver RD, Gustafson DL. Enzymology of bioreductive drug activation. Br J Cancer Suppl 1996;27:S1-8.
25. Schlager JJ, Powis G, Cytosolic NAD(P)H : (quinone acceptor)oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol. Int J Cancer 1990;45:403-9.
26. 5 reductase in human lung and breast tumours. Br J Cancer 1997;76:923-9.
27. Brunton VG, Steele G, Lewis AD, Workman P. Geldanamycin-induced cytotoxicity in human colon-cancer cell lines: evidence against the involvement of c-Src or DT-diaphorase. Cancer Chemother Pharmacol 1998;41: 417-22.
28. Monks A, Scudiero DA, Johnson GS, Paull KD, Sausville EA. The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets. Anticancer Drug Des 1997;12:533-41.
29. Traver RD, Horikoshi T, Danenberg KD, Stadibauer THW, Danenberg PV, Ross D, et al. NAD(P)H : quinone oxidoreductase gene expression in human colon carcinoma cells: characterisation of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res 1992;52: 797-802.
30. Holford J, Sharp SY, Murrer BA, Abrams M, Kelland LR. In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. Br J Cancer 1998;77:366-73.
31. Sharp SY, Rowlands MG, Jarman M, Kelland LR. Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines. Br J Cancer 1994;70:409-14.
32. Sharp SY, Smith V, Hobbs S, Kelland LR. Lack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell lines. Br J Cancer 1998;78:175-80.
33. Hobbs S, Jitrapakdee S, Wallace JC. Development of a bicistronic vector driven by the human polypeptide chain elongation factor 1α promotor for creation of stable mammalian cell lines that express very high levels of recombinant proteins. Biochem Biophys Res Commun 1998;252: 368-72.
34. Walton MI, Smith PJ, Workman P. The role of NAD(P)H : quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivalion of the novel indoloquinone antitumor agent EO9. Cancer Commun 1991;3: 199-206.
35. Beall HD, Liu Y, Siegel D, Bolton EM, Gibson NW, Ross D. Role of NAD(P)H:quinone oxidoreductase (DT-diaphorase) in cytotoxicity and induction of DNA damage by streptonigrin. Biochem Pharmacol 1996;51: 645-52.
36. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J. et al. United Kingdom Co-ordinating Committee on Cancer Research guidelines for the welfare of animals in experimental neoplasia. 2nd ed. Br J Cancer 1998;77:1-10.
37. Moscow JA, Connolly T, Myers TG, Cheng CC, Paull K, Cowan KH. Reduced folate carrier gene (RFC1) expression and anti-folate resistance in transfected and non-selected cell lines. Im J Cancer 1997;72:184-90.
38. Zou J, Guo Y, Guettouche T, Smith DF, Voellmy R. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell 1998;94: 471-80.
39. Mcllwrath AJ, Brunton VG, Brown R. Cell-cycle arrests and p53 accumulation induced by geldanamycin in human ovarian tumour cells. Cancer Chemother Pharmacol 1996;37:423-8.
40. Wallon MI, Pestell KE, Valenti MR, Brunton LA, Kelland LR, Workman P. A comparison of in vitro and in vivo techniques for assessing chemosensitivity in a genetically engineered cell line [abstract]. Proc Am Assoc Cancer Res 1999;40:407.
41. Kelsey KT, Ross D, Traver RD, Christiani DC, Zuo ZF, Spitz MR, et al. Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. Br J Cancer 1997;76:852-4.